|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute of Allergy and Infectious Diseases (NIAID) Schering-Plough |
Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00001035 |
To investigate the toxicity of interferon alfa-2b ( IFN alfa-2b ) in combination with nucleoside analog therapy in HIV-positive patients with chronic hepatitis C. To determine the efficacy of treatment with IFN alfa-2b for chronic hepatitis C in patients with advanced HIV infections treated with nucleoside analog therapy.
IFN alfa-2b has HIV inhibitory properties and has also been approved for treatment of chronic hepatitis C. Studies have shown that IFN alfa-2b is effective in asymptomatic HIV-positive patients with chronic hepatitis C, but the drug's benefit against hepatitis C in patients with advanced HIV infection has not been determined.
Condition | Intervention | Phase |
HIV Infections Hepatitis C |
Drug: Interferon alfa-2b Drug: Zidovudine Drug: Zalcitabine Drug: Didanosine |
Phase I |
MedlinePlus related topics: | AIDS Hepatitis Hepatitis C |
Drug Information available for: | Zidovudine Didanosine Interferon alfa-n1 Interferon alfa-2a Interferon alfa-2b Interferons Zalcitabine |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase I Pilot Study of the Safety and Efficacy of Interferon Alfa-2b (IFN Alfa-2b) in Combination With Nucleoside Analog Therapy in Patients With Combined Hepatitis C (HCV) and Advanced Human Immunodeficiency Virus (HIV) Infections |
Estimated Enrollment: | 10 |
IFN alfa-2b has HIV inhibitory properties and has also been approved for treatment of chronic hepatitis C. Studies have shown that IFN alfa-2b is effective in asymptomatic HIV-positive patients with chronic hepatitis C, but the drug's benefit against hepatitis C in patients with advanced HIV infection has not been determined.
Patients receive interferon alpha-2b subcutaneously 3 times weekly for 6 months. If no response is seen after 18 weeks of therapy or if an initial response is followed by relapse while on therapy, dose is increased. Patients who require a dose escalation should continue on IFN alfa-2b for an additional 6 months. All patients will also receive available nucleoside analog therapy ( zidovudine, didanosine, zalcitabine ) at currently accepted doses as clinically appropriate.
Ages Eligible for Study: | 13 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
Patients must have:
Prior Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Concurrent Medication:
Excluded:
Concurrent Treatment:
Excluded:
Prior Medication:
Excluded:
United States, Indiana | |||||
Indiana Univ Hosp | |||||
Indianapolis, Indiana, United States, 462025250 | |||||
United States, New York | |||||
Bellevue Hosp / New York Univ Med Ctr | |||||
New York, New York, United States, 10016 | |||||
Jack Weiler Hosp / Bronx Municipal Hosp | |||||
Bronx, New York, United States, 10465 | |||||
Bronx Municipal Hosp Ctr/Jacobi Med Ctr | |||||
Bronx, New York, United States, 10461 | |||||
Harlem Hosp Ctr | |||||
New York, New York, United States, 10037 | |||||
United States, Pennsylvania | |||||
Milton S Hershey Med Ctr | |||||
Hershey, Pennsylvania, United States, 170330850 | |||||
Pennsylvania State Univ / Hershey Med Ctr | |||||
Hershey, Pennsylvania, United States, 17033 | |||||
United States, Wisconsin | |||||
Great Lakes Hemophilia Foundation | |||||
Wauwatosa, Wisconsin, United States, 532130127 |
National Institute of Allergy and Infectious Diseases (NIAID) |
Schering-Plough |
Study Chair: | Gill JC | |
Study Chair: | Eyster ME |
Click here for more information about Zidovudine 
  |
Click here for more information about Didanosine 
  |
Click here for more information about Interferon alfa-2 
  |
Study ID Numbers: | ACTG 203P |
First Received: | November 2, 1999 |
Last Updated: | August 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00001035 |
Health Authority: | United States: Federal Government |
|
|
|
|
|
|